Xi'an, China

Sundian Liu

USPTO Granted Patents = 2 

Average Co-Inventor Count = 13.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
2 patents (USPTO):

Title: The Innovative Contributions of Sundian Liu

Introduction

Sundian Liu is a prominent inventor based in Xi'an, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit coronavirus activity. With a total of 2 patents, Liu's work is paving the way for advancements in antiviral treatments.

Latest Patents

Liu's latest patents include a groundbreaking compound known as 3-tetrazolylmethyl-1,3,5-triazin-2,4-dione, which effectively inhibits the activity of the coronavirus 3CL protease. This invention is crucial in the fight against SARS-CoV-2, as it blocks the replication and transcription of the virus in patients. The compound demonstrates high in-vitro safety and holds great promise for the development of anti-SARS-CoV-2 drugs. Another notable patent involves 3-triazolyl methyl-1,3,5-triazine-2,4-dione compounds, which also have significant pharmaceutical applications.

Career Highlights

Throughout his career, Sundian Liu has worked with notable companies such as Shaanxi Panlong Pharmaceutical Co., Ltd. and Xixian New District Fenghou Original Pharmaceutical Technology Co., Ltd. His experience in these organizations has contributed to his expertise in medicinal chemistry and innovation.

Collaborations

Liu has collaborated with talented individuals in his field, including Chengyuan Liang and Liang Xin. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in pharmaceutical technology.

Conclusion

Sundian Liu's contributions to medicinal chemistry and his innovative patents are vital in the ongoing battle against viral infections. His work exemplifies the importance of research and development in creating effective treatments for global health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…